Drug-coated balloons in primary percutaneous coronary intervention for acute myocardial infarction

doi:10.3969/j.issn.1006-7795.2023.04.025

Abstract

Abstract: Objective This study was to evaluate the efficacy of drug-coated balloons(DCB) for acute myocardial infarction (AMI).Methods A total of 75 AMI patients who underwent primary percutaneous coronary intervention(PCI)with DCB treatment of culprit lesion in Beijing Friendship Hospital, Capital Medical University, from August 2018 to July 2022 were enrolled in this study. The clinical data, characteristics of coronary artery lesion and prognosis were retrospectively analyzed.Results The procedural success rate was 100%, and the incidence of clinical adverse events in hospitalization was 8%. During the 30-day follow-up, 2 patients (2.7%) were readmitted for heart failure. During a median follow-up of 16 months, there were 9 cases (12%) of non-fatal myocardial infarction, 5 cases (6.7%) of target lesion revascularization, 4 cases (5.3%) of heart failure readmission, and 3 cases (4%) of stroke. The long-term cumulative main adverse cardiovascular and cerebrovascular events (MACCE) rate was 24%, and the Kaplan-Meier estimated long-term MACCE-free survival rate was 63.6%（47.3%-79.8%）. Conclusions For specific lesions in AMI, such as in-stent occlusion, small vessel disease and bifurcation lesions, DCB angioplasty in primary PCI has a high success rate and a good long-term prognosis.

Key words: drug-coated balloon, acute myocardial infarction, percutaneous coronary intervention

CLC Number:

Zhou Li, Zhu Chao, Wang Fucai, Cui Hehe, Liu Qingbo, Zhao Huiqiang, Chen Hui. Drug-coated balloons in primary percutaneous coronary intervention for acute myocardial infarction[J]. Journal of Capital Medical University, 2023, 44(4): 669-675.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.04.025

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I4/669

References

［1］陈韵岱, 王建安, 刘斌, 等. 药物涂层球囊临床应用中国专家共识［J］. 中国介入心脏病学杂志, 2016, 24(2): 61-67.
［2］ Jeger R V, Eccleshall S, Wan Ahmad W A, et al. Drug-coated balloons for coronary artery disease: third report of the International DCB Consensus Group［J］. JACC Cardiovasc Interv, 2020, 13(12): 1391-1402.
［3］ Nakazawa G, Finn A V, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study［J］. Circulation, 2008, 118(11): 1138-1145.
［4］ Gonzalo N, Barlis P, Serruys P W, et al. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography［J］. JACC Cardiovasc Interv, 2009, 2(5): 445-452.
［5］ Fang C Y, Fang H Y, Chen C J, et al. Comparison of clinical outcomes after drug-eluting balloon and drug-eluting stent use for in-stent restenosis related acute myocardial infarction: a retrospective study［J］. PeerJ, 2018, 6: e4646.
［6］ Vos N S, Dirksen M T, Vink M A, et al. Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study［J］. EuroIntervention, 2014, 10(5): 584-590.
［7］ Vos N S, Fagel N D, Amoroso G, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction: the REVELATION randomized trial［J］. JACC Cardiovasc Interv, 2019, 12(17): 1691-1699.
［8］许骥, 华琦, 胡少东, 等. 替格瑞洛在老年STEMI患者急诊PCI中的疗效与安全性分析［J］. 首都医科大学学报, 2015, 36(1): 73-77.
［9］ Gibson C M, De Lemos J A, Murphy S A, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy［J］. Circulation, 2001, 103(21): 2550-2554.
［10］ Neumann F J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)［J］. G Ital Cardiol (Rome), 2019, 20(7/8 Suppl 1): 1S-61S.
［11］ De Luca G, Suryapranata H, Stone G W, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials［J］. Int J Cardiol, 2008, 126(1): 37-44.
［12］ Scheller B, Ohlow M A, Ewen S, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial［J］. EuroIntervention, 2020, 15(17): 1527-1533.
［13］ Stefanini G G, Alfonso F, Barbato E, et al. Management of myocardial revascularisation failure: an expert consensus document of the EAPCI［J］. EuroIntervention, 2020, 16(11): e875-e890.
［14］ Joner M, Koppara T, Byrne R A, et al. Neoatherosclerosis in patients with coronary stent thrombosis: findings from optical coherence tomography imaging (a report of the PRESTIGE consortium)［J］. JACC Cardiovasc Interv, 2018, 11(14): 1340-1350.
［15］ Enomoto S, Kuramitsu S, Shinozaki T, et al. Risk factors and outcomes of recurrent drug-eluting stent thrombosis: insights from the REAL-ST registry［J］. J Am Heart Assoc, 2021, 10(9): e018972.
［16］ Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)［J］. Eur Heart J, 2018, 39(2): 119-177.
［17］ Zhang Y X, Zhang X Y, Dong Q C, et al. Duration of dual antiplatelet therapy after implantation of drug-coated balloon［J］. Front Cardiovasc Med, 2021, 8: 762391.

[1]	Ma Wei, Zhou Yifan, Jiang Huimin, Wei Huimin, Zhou Chen, Ji Xunming. Research progresses in cerebral venous sinus thrombosis animal models [J]. Journal of Capital Medical University, 2023, 44(5): 704-714.
[2]	Feng Dan, Li Na, Hou Dongyan. Correlation between residual lipoprotein cholesterol and acute myocardial infarction [J]. Journal of Capital Medical University, 2023, 44(5): 872-876.
[3]	Gao Xia, Hu Yanjin, Yao Zhi, Wang Guang. Correlation between triglyceride glucose index and severity of coronary artery disease in patients with newly diagnosed coronary heart disease [J]. Journal of Capital Medical University, 2023, 44(3): 381-386.
[4]	Wei Ying, Wang Guang. Higher hemoglobin glycation index is associated with higher risk of carotid plaques [J]. Journal of Capital Medical University, 2023, 44(3): 387-392.
[5]	Li Jie, Zhang Jun, Wang Jing, Hua Lin, Zhang Liming. Clinical analysis of renal involvement in eosinophilic granulomatosis with polyangiitis [J]. Journal of Capital Medical University, 2023, 44(3): 494-500.
[6]	Luo Xiaomeng, Jiang Xue, Du Fenghe, Guo Caixia. Levels of sRAGE and IFN-γ in the plasma of patients with acute coronary syndrome and their relationship with the severity of coronary artery lesions [J]. Journal of Capital Medical University, 2023, 44(2): 272-279.
[7]	Xu Jianke, Liu Ning, Han Miao, Zhang Hongyang, Han Xinsheng. Analysis of the relationship between non-high-density lipoprotein cholesterol and arterial plaque characteristic in a cohort of ischemic stroke patients [J]. Journal of Capital Medical University, 2023, 44(1): 49-53.
[8]	Wang Rongrong, Tian Junping. Correlation between serum calcium and cardiovascular outcome in patients with acute coronary syndrome [J]. Journal of Capital Medical University, 2023, 44(1): 154-160.
[9]	Zhao Jizong. Current status and clinical research of brain-heart comorbid vascular diseases in China [J]. Journal of Capital Medical University, 2022, 43(5): 671-673.
[10]	Feng Li, Yang Jiaxue, Li Xin, Jia Changqi, Jiang Chenxi. Functional change of hERG1a mutation H70R on hERG1a homomeric current and hERG1a/1b heteromeric currents [J]. Journal of Capital Medical University, 2022, 43(5): 747-753.
[11]	Ma Yixin, Zhang Zhongying, Si Sicong, Luo Hongyu, Zhao Huan, Yang Wei. The relationship between the new adipokines visfatin and vaspin expression in patients with type 2 diabetes mellitus and left ventricular hypertrophy [J]. Journal of Capital Medical University, 2022, 43(5): 767-773.
[12]	Chen Lu, Guo Xinying, Liu Jian, Du Fenghe, Guo Caixia. Correlation analysis of soluble advanced glycation end product receptors and renal function in patients with coronary atherosclerotic heart disease [J]. Journal of Capital Medical University, 2022, 43(2): 167-172.
[13]	Su Wen, Li Hongwei, Chen Hui, Li Weiping. Effect of D-dimer on long-term prognosis in patients with acute myocardial infarction [J]. Journal of Capital Medical University, 2022, 43(2): 173-177.
[14]	Wang Qian, Zhang Jiakun, Liu Qing, Sun Lin, Li Jingjie. M2 macrophage promotes myocardial regeneration by modulating nerve regeneration and angiogenesis in neonatal mice [J]. Journal of Capital Medical University, 2022, 43(2): 178-186.
[15]	Ren Chunqi, Kong Yu, Fu Shenggao, Zhu Zhengyan, Du Xin. Clinical characteristics and risk factors of young and middle-aged patients with calcified aortic valve disease [J]. Journal of Capital Medical University, 2022, 43(2): 187-191.